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Abstract
Background: The clinical course of cystic fibrosis (CF) shows considerable variation resulting in differences in health care
utilisation. We investigated important clinical parameters and their relation to costs. Methods: We collected clinical parameters
together with health care utilisation of a representative paediatric CF population (ns138 patients) attending Hanover Medical
School over a period of 1 year. 49% of the patients were chronically infected with Pseudomonas aeruginosa. Costs were
calculated on the basis of the annual individual health care utilisation from the perspective of health insurance. Results: Total
annual expenditure per patient amounted to 723,989 (S.D. 18,026), with home drug treatment representing the most important
single cost factor (47% of total costs). While costs rose with age and doubled in the first 18 years, they correlated foremost with
P. aeruginosa airway colonisation status and lung function expressed as FEV . Costs of patients with chronic P. aeruginosa1
infection were more than three times higher than of uninfected patients. Conclusions: Health care expenditures for patients with
CF vary with the clinical course. The variation can be explained to a large extend by clinical parameters.
 2003 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Life expectancy of patients with cystic fibrosis (CF)
has improved considerably during the past decades
following the introduction of a number of therapeutic
measures including pancreatic enzyme supplementation,
antibiotic therapy and mucolytic drugs w1x. Consequent-
ly, the increased prevalence of CF together with newly
introduced therapies have augmented health care utilis-
ation and expenditure.
The clinical course of CF is known to vary consid-
erably even under similar standards of care w2x. Although
in Germany almost half of the CF patients (47%) now
reach adulthood with a lung function value within the
normal range (forced expiratory volume in 1 s, FEV ,1
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)80% predicted), a third still die below the age of 18
years w3x. Patients with moderate or advanced lung
disease appear to have more frequent health care utilis-
ation including more frequent clinic visits and hospital
stays w4x.
In the assessment of new health care interventions
such as new therapies or screening programmes, data
on medical consumption and their related costs are
required to estimate their economic impact. Health care
interventions lead to direct costs, but they may also
have a positive or negative impact on costs of conven-
tional therapy. Since outcome measures of clinical trials
frequently consist of clinical parameters, such as FEV ,1
infection status, or nutritional status, it is important to
evaluate the relationship between clinical parameters
and costs of care. We hypothesised that health care
expenditures for patients with CF vary with the clinical
course and investigated the relevance of clinical para-
meters in predicting annual treatment costs. We dem-
onstrate in a paediatric CF population that a selection
of parameters can explain over 60% of the variation of
costs.
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Table 1
Mean (S.D.) FEV , weight index and status of P. aeruginosa infection1
in different age groups of the study population and of the paediatric
population of the German CF registry
Age FEV1 Weight Chronic n
wyearsx w% pred.x index P. aeruginosa
infection w%x
-3 – 95.0 (9.1) 25 20
3–6 – 95.8 (8.8) 29 21
6–9 97.1 (22.5) 95.5 (9.4) 13 16
9–12 93.6 (16.1) 94.4 (12.9) 52 27
12–15 82.5 (19.4) 94.5 (11.0) 65 17
)15 72.7 (26.4) 94.0 (16.7) 78 37
Mean (S.D.) 84.5 (23.8) 94.7 (12.3) 48.6 138
German CF 79.7 (23.5) 97.0 (11.6) 48.3 2358
registry
For definition of chronic P. aeruginosa infection refer to Section 2.
2. Materials and methods
2.1. Subjects
The study was located at the cystic fibrosis clinic of
the Paediatric Department of Hanover Medical School.
This is one of the three largest units in Germany, serving
a population of approximately 10 million in a model of
shared care. All patients who regularly attended the unit
were included in this study. Exclusion criteria were
additional diseases unrelated to CF that may incur
significant costs or a shared care with other CF-centres
in order not to miss health care consumption documented
elsewhere. The patients were seen in the CF clinic four
times per year on a regular basis. At each visit, lung
function tests, anthropometrical measures and sputum or
throat swab cultures were performed. Lung function
values were corrected for height, weight and gender and
calculated as percent of predicted values w5x. Nutritional
status was determined as percentage of ideal weight
corrected for height, age and gender w6x. Chest radio-
graphs were evaluated according to the scoring system
of Crispin and Norman by a single experienced radio-
logist w7x. Patients were considered chronically infected
with P. aeruginosa if more than 50% of cultures were
positive in the preceding 12 months. Patients with
positive cultures of less than 50% were rated intermit-
tently colonised w8x. Chronically infected patients were
treated with either inhaled tobramycin (80 mg b.d.) or
colistin (10 U b.d.). Patients with chronic P. aeruginosa6
infection and clinical exacerbation defined as deteriora-
tion of lung function were treated with intravenous
antibiotics for 2 weeks, which was repeated in 3-month
intervals.
Out of the ns196 patients seen in the unit in 1996,
all patients who received care only by this unit wns
138, ns74 (54%) malex were included in the study.
The excluded patients were either seen in a model of
shared care also by other units (ns55), or suffered also
from a second disorder (leukaemia, cerebral palsy and
psychosis, respectively, ns3). Mean age was 10.1 years
(S.D. 5.6, range 0–18), with a mean FEV of 84.5%1
(S.D. 23.8, range 23–125, ns101). Weight index
ranged from 70 to 143%, with a mean of 94.7% (S.D.
12.3). 67 (48.6%) patients were chronically infected
with P. aeruginosa, another 15 (10.9%) intermittently.
As expected, FEV declined with age, while rate of1
chronic infection with P. aeruginosa rose (Table 1).
Comparisons between the study population and the
German CF registry of the same year (ns2358) showed
no consistent differences for age and the rate of chronic
P. aeruginosa infection w9x. However, there were slight
differences in mean FEV and nutritional status (Table1
1).
2.2. Assessment of health care consumption
Data on diagnostic and other health care services were
retrieved from databases of the hospital administration,
seven diagnostic departments, the clinical database of
the CF unit and the patients’ records. Data on external
services were obtained from the patients’ records. In
addition, the families were asked to document the visits
to their local general practitioner, physiotherapist and
the utilisation of health care aids.
This retrieval resulted in over 21,000 documented
diagnostic procedures of 181 categories and approxi-
mately 3800 documented prescriptions of 61 different
drugs.
2.3. Calculation of costs
Costs were calculated from the perspective of health
care insurances. Although the German health care mar-
ket is largely regulated, there is some variation in prices
depending on the health insurance. Public insurances
reimburse out-patient services on a fee-for-service basis
with largely fixed prices w10x, and inpatient services by
an overall fee for each hospital day (7536 in this
study). Fees for privately insured patients allow for
some variation in both the out- and inpatient sector w11x.
Prices for outpatient drugs are generally fixed w12x.
Medical consumption was therefore stratified to the
in- and outpatient sector and the health care expenses
calculated separately for patients with public and private
health care insurance, respectively. The proportion of
patients in our study covered by public insurances was
98% (ns135), which was slightly higher than the
proportion in the general German population (94%).
Due to the fixed prices for reimbursement by public
health insurances, expenses could be calculated with
high accuracy. Expenses for the three study patients
with private health insurance were directly obtained
from the bills invoiced to the patients.
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Table 2
Mean (S.D.) medical consumption per patient over 1 year, stratified by outpatient and inpatient (hospital) care
Outpatient Inpatient Sum
IV-antibiotic therapy wdaysx 0.3 (1.7) 12.5 (17.6) 12.7 (17.9)
Oral antibiotic therapy wdaysx 254.9 (125.8) 12.6 (19.1) 267.7 (132.2)
Inhaled antibiotic therapy wdaysx 211.6 (168.4) 13.4 (17.4) 225.0 (176.7)
Dornase alpha therapy wdaysx 12.9 (54.6) 1.1 (6.4) 13.9 (59.6)
Lung function tests wNo.x 2.7 (2.3) 2.0 (3.0) 4.7 (4.0)
Radiographs wNo.x 0.5 (0.6) 0.6 (2.0) 1.2 (2.3)
Ultrasound scans wNo.x 0.4 (.6) 0.7 (0.9) 1.1 (1.0)
Microbiological tests wNo.x 5.1 (2.6) 5.4 (7.3) 10.5 (7.6)
Blood tests wNo.x 49.6 (38.5) 61.5 (92.9) 111.1 (111.2)
Costs were aggregated to annual costs on the basis of
a 1-year observation period in 1996–1997, together with
the related prices and converted into Euro (1 7s
1.95583 DM). Mean values of clinical data were used
if several measures were obtained in that year. Long-
term costs and life years gained were calculated with an
annual discount rate of 5% w13x.
2.4. Statistics
Data were compiled in a relational database. Normal
distribution of data was analysed by the Shapiro–Wilk
test. Groups were compared by the two-sided unpaired
Student’s T-test following Levines’ test of equality of
variances. Ordinal and least square linear regression
analysis was used for analysis of dependence of cost
data from clinical variables. For stepwise multiple
regression analysis, ordinal variables were transformed
into a set of variables indicating the presence or absence
of a single value of the original ordinal variable. Bivar-
iate correlations were calculated with the Pearson’s
coefficient. Calculations were performed with the Statis-
tical Package for Social Sciences (SPSS, V. 11).
3. Results
3.1. Medical consumption
Patients attended the CF outpatient-clinic on average
3.3 times per year (S.D. 1.3, range 0–7). Hospital care
amounted to 14.4 days (S.D. 18.4, range 0–96), com-
monly in combination with intravenous antibiotic treat-
ment. Patients performed on average 4.7 lung function
tests wpatients )6 years: 6.2 (3.6), ns97x. In addition,
1.2 radiographs, 1.1 ultrasound scans, 10.5 microbacter-
ial cultures and 111.1 blood tests per patient were
performed. Medical services used by the patients in CF
clinic, hospital care and at home are summarised in
Table 2.
3.2. Total annual costs
Total annual expenditure per patient amounted to
723,989 (S.D. 18,026), with outpatient care accounting
for 59% (714,222, S.D. 9368), and 79767 (S.D.
11,811) for hospital care. 47% of total expenditure was
spent on outpatient drugs, with costs for inhaled antibi-
otics and pancreatic enzymes being the most expensive
single drugs (38 and 22% of drug expenditure, respec-
tively). Dornase alpha contributed 4.7% to the total
drug expenditure. Other costs for outpatient services
were comparatively small, with charges of the CF clinic
accounting for 2% of total expenses of the health
insurance (Fig. 1). As shown in Fig. 2, total costs rose
with age and almost doubled within the first 18 years.
This was mainly due to the tripling costs of home drug
therapy, and to more frequent and prolonged hospital
stays. Outpatient costs other than drug expenditure,
however, remained largely unchanged. Children -3
years had higher costs for hospital care than children
from 3 to 9 years, mostly due to hospital stays in
relation to establishing the diagnosis.
3.3. Analysis of clinical determinants of cost levels
Male and female patients did not differ with regard
to total costs. There was a moderate correlation between
age and total costs (rs0.42, P-0.001). We speculated
that the rise in costs was due to both increased drug
dosages along with weight increase and to progress of
disease. However, anthropometric measures failed to
correlate with total costs (weight: rs0.052; length: rs
0.022; body surface: rs0.007; Psn.s.). In contrast,
costs were highly related to progression of lung disease,
as demonstrated by a negative correlation to FEV (rs1
y0.71, P-0.001, Fig. 3a), or a score for radiological
signs of lung pathology (Crispin–Norman score, rs
0.633, P-0.001), together explaining 49% of variance
of cost. Nutritional status, however, was only marginally
related to the cost of therapy (rs0.24, Ps0.005, Fig.
3b).
Since P. aeruginosa airway infection may lead to both
a progress of lung disease and intensified therapy, we
determined the treatment costs in relation to the P.
aeruginosa colonisation status. Annual costs of patients
who were not colonised (ns56) were relatively low
710,861 (S.D. 7105) and showed no age-related
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Fig. 1. Cost of care of CF from the perspective of health insurance.
Fig. 2. Age-specific total annual costs divided by sector of care.
Fig. 3. Total annual costs from the perspective of health insurance in relation to FEV (a) and nutritional index (b).1
increase (Fig. 4). In contrast, annual costs of chronically
colonised patients were three times as high (736,421,
S.D. 17,449, ns67), while costs of intermittently infect-
ed patients (ns15) were only slightly above the level
of uninfected patients (717,476, S.D. 8447). In regres-
sion analysis, status of colonisation with P. aeruginosa
explained 44% of differences in total costs, being a
much stronger predictor than age (Table 3). Thus, the
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Table 3
Ordinal (colonisation status) and linear (other parameters) regression
analysis between clinical parameters and total costs
Parameter R 2 P Sum of R 2
Colonisation status 0.54 -0.001
FEV1 0.50 -0.001 0.62
Crispin Norman score 0.38 -0.001 0.63
Age 0.15 -0.001 0.64
Nutritional index 0.05 0.006 0.64
Parameters are listed according to the amount of variance explained
in single regression analysis (R ). The sum of R was calculated by2 2
multiple stepwise regression analysis.
Fig. 4. Mean (S.D.) total annual cost from perspective of health insurance depending on age and status of colonisation with P. aeruginosa. Costs
of chronically infected patients were significantly different to costs of intermittently infected and to costs of uninfected patients for all age groups
(P-0.05, * and †, respectively). Mean costs of intermittently infected patients were significantly different to uninfected in age group 6–12 years
(‡). Comparison of different age groups with the same status of infection revealed significant differences only for intermittently and chronically
infected patients (age -6 vs. both older groups, P-0.05), and intermittently infected patients (age -6 vs. age 6–12, P-0.05, not indicated).
age-dependent rise of costs of the study population was
largely due to the increasing proportion of patients with
chronic P. aeruginosa infection (Fig. 4).
3.4. Lifetime cost of cystic fibrosis from the perspective
of health insurance
On the basis of age-specific annual costs (Fig. 2), the
aggregated and annually discounted costs of treatment
from age 0 to 18 years are 7252,023. To extrapolate the
data into adulthood, we hypothesised that medical con-
sumption largely depends on the stage of disease and
that the therapy of adolescents is not fundamentally
different to adult treatment. Compared to the German
adult CF patients, the adolescent patients with a patho-
logical lung function (age above 15 years, FEV -80%,1
ns22) had comparable mean (S.D.) FEV w54% (23.7)1
vs. 56% (17.7)x and a higher P. aeruginosa colonisation
rate (75 vs. 86%) w9x. Annual costs of this cohort were
739,439 (S.D. 21,748). When annual costs of this
cohort were extrapolated to the median predicted surviv-
al age of 32 years w3x, lifetime expenditures amount to
approximately 7396,000.
3.5. Annual cost of CF in Germany
In the annual national registry 2,358 patients aged
below 18 years are documented w9x. Based on the costs
determined in this study, annual expenditure for these
patients amount to 756.6 million, which was approxi-
mately 0.038% of the German health insurance budget
of that year (7150 billion) w14x. Extrapolation of annual
costs of CF patients including adults (ns3582) leads
to total annual costs for CF of 7105 million or 0.07%
of the budget.
3.6. Cost effectiveness analysis: cost per year of life
gained
Prior to the introduction of enzyme substitution and
antibiotic therapy, the natural course of cystic fibrosis
frequently resulted in death in early childhood. Today,
due to a number of therapeutic measures, which have
been calculated in this study, the median predicted
survival age has risen to over 30 years in industrialised
nations w3,4,15x. If life expectancy of an untreated
patient is estimated as 3 years, the sum of (discounted)
years gained by a life long therapy amounts to 14.3
years. Thus the cost of each gained year is approximately
731,000.
3.7. Sensitivity analysis
Although the calculations of costs in this study are
based on the actual utilisation of health care resources
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and therefore relatively accurate, extrapolation to a
national level bears more uncertainties that have to be
addressed in sensitivity analyses. Important aspects of
therapy such as the use of oral antibiotics and pancreatic
enzymes were comparable between the study population
and the data of the national survey. Differences, how-
ever, were found in the frequency of treatment with
inhaled antibiotics (study group 47%, national report
24%), and dornase alpha (8% vs. 20%). Calculation of
annual costs according to the average utilisation of these
two therapies in the national survey would increase the
total annual costs per patient by 7500, or less than 2%.
Hospital treatment occurred predominantly in the Pae-
diatric Department of Hanover Medical School, account-
ing for 87% of all expenditures for hospital treatment
and approximately a third of total costs. As a tertiary
centre, fees for care in this institution are relatively high.
If hospital care would have occurred elsewhere at a 20%
lower fee, total annual costs per patient would have
decreased by 6.5% or 71700. Krauth et al. estimated
the costs of 14 days of hospital treatment as 79564 for
a German adult population, which is virtually identical
to the costs in our study w16x. According to these
sensitivity analyses, our data appear to be representative
within a range of 10%.
4. Discussion
We investigated the costs of cystic fibrosis paediatric
patients from the perspective of health care insurance
and determined the differences between various stages
of disease. Costs rose considerably with age, but the
increase depended largely on the rising morbidity as
reflected by P. aeruginosa colonisation status and lung
function.
The finding that costs increase with disease severity
or age has also been described by others. A recent
American study classified patients according to their
FEV into three groups, reporting considerably increased1
costs in patients with severe lung disease (FEV -40%)1
w17x. A Dutch cross-sectional study analysed the relation
of costs to age and showed a marked increase after the
age of 15 years w18x. From the perspective of a health
care provider, a UK study reported high costs for adult
patients with a high level of care w19x.
A strength of this study is that it combines economic
and several clinical aspects of cystic fibrosis therapy.
FEV is the primary outcome parameter in numerous1
clinical studies, and it also appears to be an acceptable
determinant of treatment costs. Costs hardly change with
age in patients who preserve a good lung function.
Patients who become colonised with P. aeruginosa,
however, are frequently commenced on expensive anti-
biotic drug therapy. From the clinician’s point of view,
it may be surprising that nutritional status was largely
unrelated to treatment costs although a relationship
between nutritional status and lung function has been
repeatedly described w20x. Extensive (and expensive)
treatment such as intravenous and inhaled antibiotic
therapy, however, is commenced prior to a clinical
condition, where weight deteriorates.
With differences between health care systems, this
study may not be representative outside the German
borders. Studies performed in other countries, however,
report surprisingly similar structures of CF-related costs
with comparable proportions of hospital care, drugs and
total expenses w17–19x. A Dutch study reported 13.4
days of hospital treatment for CF patients aged below
20 years w18x, which is in the same range as our data
(14.4 days). While the Dutch data lead to a similar
estimation of CF treatment costs in relation to the total
health care budget, as in our study w18x, average costs
in an English and American study were lower. The
British National Health Service, or an American health
maintenance organisation may operate at relatively low
costs compared to the German health care system, with
a high priced drug market and a fee-for-service reim-
bursement in outpatient care.
The current mortality is a result of therapeutic efforts
that have been undertaken over the past 30 years, but
our cost effectiveness analysis employs the costs of
current therapy. With a potential further rise in life
expectancy the cost per gained year of life may evolve
differently in the future. Since every gained year induces
another year of treatment, lifetime costs are likely to
increase with further advances of therapy, for instance
the more widespread use of lung transplantation. Costs
per year gained, however, may decrease, particularly if
preventive strategies succeed in delaying onset of chron-
ic P. aeruginosa infection w21,22x. Delaying onset of P.
aeruginosa infection by 1 year would save more than
725,000 per patient, equivalent to the difference of
average annual costs for an chronically vs. uninfected
patient. If a prevention programme for the German CF
population -18 years succeeded in delaying the onset
of infection by 1 year, the marginal costs could be up
to 730 million to break even with the achieved savings
in this age group.
In summary, the data from this study argue for the
enhancement of strategies aimed at preventing either
decline of FEV or onset of P. aeruginosa infection. If,1
for instance, an effective vaccine was developed, it may
be more cost effective than limiting lung disease once
chronic infection has been established.
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